サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1236902

肺動脈性肺高血圧症（PAH）治療薬市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 143 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
肺動脈性肺高血圧症（PAH）治療薬市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年02月21日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肺動脈性肺高血圧症（PAH）治療薬の世界市場規模は2022年に73億米ドルに到達今後、IMARCグループは、2023年から2028年にかけて5.2%の成長率（CAGR）を示し、2028年までに99億米ドルに達すると予測しています。

肺動脈性肺高血圧症（PAH）は、心臓と肺をつなぐ動脈の高血圧を特徴とする、生命を脅かす病状を指します。肺動脈性肺高血圧症（PAH）は、心臓と肺をつなぐ動脈の血圧が高くなることで、動脈の壁が締め付けられ狭くなり、血液を送り出す心臓にさらなる圧力がかかり、筋肉が弱くなります。最悪の場合、血液を送り出す心臓の機能が低下し、最終的に心不全を引き起こすこともあります。PAHは、息切れ、疲労感、足首や脚のむくみなどを特徴とします。心エコー図検査、コンピューター断層撮影（CT）検査、胸部X線検査、換気-灌流検査など、さまざまな検査によって診断されます。通常、エンドセリン受容体拮抗薬（ERA）、血管拡張薬、カルシウム拮抗薬（CCB）、抗凝固薬、利尿薬、心配糖体など、さまざまな薬剤を用いて治療します。これらの薬剤は、吸入、注射、経口投与が可能です。

心血管疾患や肺疾患の有病率の増加は、市場の成長を促進する重要な要因の1つです。さらに、このような病気にかかりやすい老年人口が増加していることも、市場の成長を後押ししています。また、過度の飲酒、運動不足、不健康な食事パターンなどのライフスタイルの変化が、高血圧や高脂血症のリスクを高めています。これに加えて、PAH治療のための新しいオーファンドラッグや技術的に高度な機器の開拓が、市場の成長を後押ししています。また、PAHの治療法に関する一般市民の意識の高まりや、世界のヘルスケアインフラの改善なども、市場をさらに牽引すると期待されています。

主要市場のセグメンテーション

  • IMARC Groupは、肺動脈性肺高血圧症（PAH）治療薬の世界市場レポートの各サブセグメントにおける主要動向の分析と、2023年から2028年までの世界、地域、国レベルでの予測を掲載しています。当レポートでは、薬剤クラス、投与経路、エンドユーザーに基づき、市場を分類しています。

本レポートで回答した主な質問

  • 世界の肺動脈性肺高血圧症（PAH）治療薬市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19が世界の肺動脈性肺高血圧症（PAH）治療薬市場に与えた影響とは？
  • 主要な地域市場とは？
  • 薬物クラスに基づく市場の内訳は？
  • 投与経路に基づく市場の内訳は？
  • エンドユーザー別の市場内訳は？
  • 業界のバリューチェーンにおける様々なステージは？
  • 業界における主要な促進要因と課題は何か？
  • 世界の肺動脈性肺高血圧症（PAH）治療薬の市場構造と主要プレイヤーは？
  • 業界における競合の程度は？

目次

第1章 序文

第2章 スコープと調査手法

  • 調査目的
  • 利害関係者について
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主な業界動向

第5章 肺動脈性肺高血圧症（PAH）治療薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響について
  • 市場予測

第6章 薬剤クラス別市場内訳

  • エンドセリン受容体拮抗薬（ERA）
    • 市場の動向
    • 市場予測
  • 血管拡張剤
    • 市場の動向
    • 市場予測
  • ホスホジエステラーゼ-5（PDE-5）阻害剤
    • 市場の動向
    • 市場予測
  • 可溶性グアニル酸シクラーゼ（sGC）刺激剤
    • 市場の動向
    • 市場予測
  • カルシウム拮抗薬（CCB）
    • 市場の動向
    • 市場予測
  • プロスタサイクリンおよびプロスタサイクリンアナログ
    • 市場の動向
    • 市場予測
  • その他
    • 市場の動向
    • 市場予測

第7章 投与経路別市場内訳

  • 吸入
    • 市場の動向
    • 市場予測
  • 注入
    • 市場の動向
    • 市場予測
  • 経口投与
    • 市場の動向
    • 市場予測

第8章 エンドユーザー別市場内訳

  • 病院
    • 市場の動向
    • 市場予測
  • クリニック
    • 市場の動向
    • 市場予測
  • その他
    • 市場の動向
    • 市場予測

第9章 地域別の市場内訳

  • 北米
    • 米国
      • 市場の動向
      • 市場予測
    • カナダ
      • 市場の動向
      • 市場予測
  • アジア太平洋地域
    • 中国
      • 市場の動向
      • 市場予測
    • 日本
      • 市場の動向
      • 市場予測
    • インド
      • 市場の動向
      • 市場予測
    • 韓国
      • 市場の動向
      • 市場予測
    • オーストラリア
      • 市場の動向
      • 市場予測
    • インドネシア
      • 市場の動向
      • 市場予測
    • その他
      • 市場の動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場の動向
      • 市場予測
    • フランス
      • 市場の動向
      • 市場予測
    • 英国
      • 市場の動向
      • 市場予測
    • イタリア
      • 市場の動向
      • 市場予測
    • スペイン
      • 市場の動向
      • 市場予測
    • ロシア
      • 市場の動向
      • 市場予測
    • その他
      • 市場の動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場の動向
      • 市場予測
    • メキシコ
      • 市場の動向
      • 市場予測
    • その他
      • 市場の動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場の動向
    • 国別の市場内訳
    • 市場予測

第10章 SWOT分析

  • 概要
  • ストレングス
  • 弱点
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターズファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の度合い
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢について

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Actelion Pharmaceuticals Ltd（Johnson & Johnson）
    • Arena Pharmaceuticals Inc.
    • AstraZeneca PLC
    • Bayer Aktiengesellschaft
    • Daiichi Sankyo Company Limited
    • Gilead Science Inc.
    • GlaxoSmithKline PLC
    • Merck KGaA
    • Novartis International AG
    • Pfizer Inc.
    • United Therapeutics Corporation
図表

List of Figures

  • Figure 1: Global: Pulmonary Arterial Hypertension Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 4: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Route of Administration (in %), 2022
  • Figure 5: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by End User (in %), 2022
  • Figure 6: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Region (in %), 2022
  • Figure 7: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 8: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: North America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: North America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: United States: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: United States: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Canada: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Canada: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: China: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: China: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Japan: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Japan: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: India: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: India: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: South Korea: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: South Korea: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Australia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Australia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Indonesia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Indonesia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Europe: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Europe: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Germany: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Germany: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: France: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: France: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: United Kingdom: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: United Kingdom: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Italy: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Italy: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Spain: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Spain: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Russia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Russia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Latin America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Latin America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Brazil: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Brazil: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Mexico: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Mexico: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Global: Pulmonary Arterial Hypertension Drugs Industry: SWOT Analysis
  • Figure 83: Global: Pulmonary Arterial Hypertension Drugs Industry: Value Chain Analysis
  • Figure 84: Global: Pulmonary Arterial Hypertension Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pulmonary Arterial Hypertension Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 4: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Pulmonary Arterial Hypertension Drugs Market Structure
  • Table 7: Global: Pulmonary Arterial Hypertension Drugs Market: Key Players
目次
Product Code: SR1523A167_Report

The global pulmonary arterial hypertension (PAH) drugs market size reached US$ 7.3 Billion in 2022 Looking forward, IMARC Group expects the market to reach US$ 9.9 Billion by 2028, exhibiting a growth rate (CAGR) of 5.2% during 2023-2028.

Pulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs. It causes the artery walls to tighten and narrow down, thereby exerting additional pressure on the heart to pump blood and weakening the muscles. In adverse cases, it can also compromise the heart's capacity to pump blood, thus eventually causing heart failure. PAH is characterized by shortness of breath, fatigue and swelling in ankles and legs. It is diagnosed through various tests, such as an echocardiogram, computer tomography (CT) scans, chest X-rays and ventilation-perfusion scans. It is usually treated using various drugs, such as endothelin receptor antagonists (ERAs), vasodilators, calcium channel blockers (CCBs), anticoagulants, diuretics and cardiac glycosides. These drugs can be inhaled, injected or orally administered.

The increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population that is more susceptible to such medical ailments is providing a boost to the market growth. In line with this, changes in lifestyles, such as excessive alcohol consumption, a lack of physical activity, and unhealthy dietary patterns, have enhanced the risks of hypertension and high blood pressure. This, along with the development of novel orphan drugs and technologically advanced devices for the treatment of PAH, is favoring the market growth. Other factors, including increasing awareness among the masses regarding the available treatment alternatives for PAH, and improving healthcare infrastructure across the globe, are expected to drive the market further.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global pulmonary arterial hypertension (PAH) drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, route of administration and end user.

Breakup by Drug Class:

  • Endothelin Receptor Antagonists (ERAs)
  • Vasodilators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators
  • Calcium Channel Blockers (CCBs)
  • Prostacyclin and Prostacyclin Analogs
  • Others

Breakup by Route of Administration:

  • Inhalation
  • Injectable
  • Oral Administration

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.

Key Questions Answered in This Report:

  • How has the global pulmonary arterial hypertension (PAH) drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global pulmonary arterial hypertension (PAH) drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global pulmonary arterial hypertension (PAH) drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Endothelin Receptor Antagonists (ERAs)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vasodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Soluble Guanylate Cyclase (sGC) Stimulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Calcium Channel Blockers (CCBs)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Prostacyclin and Prostacyclin Analogs
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Inhalation
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral Administration
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Actelion Pharmaceuticals Ltd (Johnson & Johnson)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Arena Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca PLC
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bayer Aktiengesellschaft
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Daiichi Sankyo Company Limited
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Gilead Science Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 GlaxoSmithKline PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck KGaA
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis International AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 United Therapeutics Corporation
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis